Gyre Therapeutics (GYRE) Net Margin (2010 - 2026)

Gyre Therapeutics (GYRE) has 16 years of Net Margin data on file, last reported at 38.59% in Q1 2026.

• Net Margin for Q1 2026 came in at 38.59%, down 5083.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 5.44% (down 1264.0% YoY), and the FY2025 annual result was 4.31%, down 712.0% from the prior year.
• Net Margin declined to 38.59% in Q1 2026 per GYRE's latest filing, from 4.63% in the prior quarter.
• Over five years, Net Margin peaked at 27.72% in Q1 2024 and troughed at 1830.73% in Q1 2022.
• A 5-year average of 145.09% and a median of 4.41% in 2024 frame the typical range for Net Margin.
• On a YoY basis, Net Margin climbed as much as 183973 bps in 2023 and fell as far as 34259 bps in 2023.
• A 5-year view of Net Margin shows it stood at 29.47% in 2022, then tumbled by 1163 bps to 372.06% in 2023, then surged by 100 bps to 0.36% in 2024, then slumped by 1204 bps to 4.63% in 2025, then sank by 733 bps to 38.59% in 2026.
• Business Quant data shows GYRE's Net Margin at 38.59% in Q1 2026, 4.63% in Q4 2025, and 11.81% in Q3 2025.